Table 2.
Baseline demographic and clinical characteristics of participants randomly assigned to receive dietary potassium restriction or standard care
| Clinical Variables | Control, n=24 | Potassium Restriction, n=23 |
|---|---|---|
| Age,a yr | 66 (52–68) | 67 (57–69) |
| Women, n (%) | 7 (29) | 10 (43) |
| Body mass indexb | 33.5±8.4 | 34.6±8.7 |
| Diabetes, n (%) | 12 (50) | 11 (47) |
| Systolic BP, mmHg | 123±15 | 131±14 |
| Diastolic BP, mmHg | 71±10 | 71±9 |
| eGFR, ml/min per 1.73 m2 | 36±9 | 33±8 |
| Serum creatinine, mg/dl | 1.9±0.4 | 2.0±0.5 |
| Serum potassium, mEq/L | 4.7±0.5 | 4.7±0.4 |
| 24-h Urinary potassium,c mEq/24 h | 69±24 | 60±25 |
| Renin-angiotensin-aldosterone system inhibitor use during enrolment period, n (%) | 8 (33) | 13 (57) |
| Diuretic use during enrolment period, n (%) | 1 (4) | 1 (4) |
| Neurologic variables,d % | ||
| No neuropathy (score <2), n (%) | 5 (24) | 6 (29) |
| Neuropathy (score ≥2), n (%) | 16 (76) | 15 (71) |
| Dietary variablesd | ||
| Dietary potassium, mg/d | 4119±1158 | 4710±1998 |
| Dietary sodium, mg/d | 2452±1149 | 3059±1124 |
| Protein, g/d | 122±42 | 112±40 |
| Energy,a kcal | 1247 (314–1849) | 521 (281–1722) |
| Subjective global assessment (% well nourished), n (%) | 18 (86) | 21 (100) |
Continuous variables are summarized as mean±SD, and all P values are >0.10.
a
Indicates variables that are not normally distributed and are summarized as median (interquartile range).
b
n=22 and n=21 patients, respectively.
c
n=15 and n=16 patients, respectively.
d
n=21 for both groups for all neurologic and dietary variables.